The FDA approves Kyowa Kirin’s (OTCPK:KYKOF) Nourianz (istradefylline) tablets as an add-on treatment to levodopa/carbidopa for adults with Parkinson’s disease (PD) who are experiencing “off” episodes.
An “off” episode is when a PD patient’s medication is not working well and symptoms return.
The FDA nod is a win for the company considering its first application was rejected in 2008 over efficacy questions and a 2016 study failed to demonstrate a significant treatment effect versus placebo.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.